📊 NAMSW Key Takeaways
Is NewAmsterdam Pharma Co N.V. (NAMSW) a Good Investment?
NewAmsterdam Pharma exhibits catastrophic operational deterioration with 50.6% YoY revenue collapse to $22.5M and a -$225.7M operating loss generating -1002.9% operating margin. The company is burning $148M annually in negative free cash flow, making current operations fundamentally unsustainable despite a $490M cash cushion. The magnitude of losses relative to revenue indicates severe business model dysfunction requiring dramatic operational restructuring or successful pipeline catalysts to justify investment.
NewAmsterdam shows a very strong balance sheet with $490M cash, no debt, and exceptional liquidity, providing a multi-year runway at the current burn. However, fundamentals remain weak: revenue fell 50% YoY and profitability is deeply negative with >900% net margin loss and sizable operating cash burn. Without clearer visibility to sustainable revenue or materially lower OpEx, continued losses and potential dilution risks outweigh the strong cash position.
NewAmsterdam Pharma Co N.V. Key Strengths (NAMSW)
- Strong cash position of $490M provides 3-4 year runway even at current burn rate
- Minimal debt exposure with 0.00x debt-to-equity ratio and $85.9M total liabilities
- Excellent liquidity metrics with 7.88x current and quick ratios provide financial flexibility
- Robust cash balance and liquidity (7.9x current ratio)
- Debt-free capital structure with low liabilities
- Runway supported despite minimal capex and high equity base
NAMSW Stock Risks: NewAmsterdam Pharma Co N.V. Investment Risks
- Revenue collapse of 50.6% YoY to $22.5M indicates severe product, market, or competitive challenges
- Operating loss of $225.7M on minimal revenue demonstrates fundamental business model breakdown
- Negative operating cash flow of -$147.8M shows unsustainable cash burn that will deplete reserves despite strong balance sheet
- Persistent large operating losses and deeply negative margins
- Revenue contraction and low quality/visibility of revenue streams
- Ongoing cash burn raises future financing/dilution risk
Key Metrics to Watch
- Revenue stabilization and pathway to positive growth
- Operating cash flow trends and rate of cash reserve depletion
- Pipeline clinical trial results and regulatory approvals driving potential business recovery
- Quarterly operating cash burn and cash runway
- Operating expenses (R&D/SG&A) and operating margin trajectory
NewAmsterdam Pharma Co N.V. (NAMSW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.88x current ratio provides a solid financial cushion.
NAMSW Profit Margin, ROE & Profitability Analysis
NAMSW vs Healthcare Sector: How NewAmsterdam Pharma Co N.V. Compares
How NewAmsterdam Pharma Co N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NewAmsterdam Pharma Co N.V. Stock Overvalued? NAMSW Valuation Analysis 2026
Based on fundamental analysis, NewAmsterdam Pharma Co N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NewAmsterdam Pharma Co N.V. Balance Sheet: NAMSW Debt, Cash & Liquidity
NAMSW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NewAmsterdam Pharma Co N.V.'s revenue has declined by 56% over the 5-year period, indicating business contraction. The most recent EPS of $-2.15 indicates the company is currently unprofitable.
NAMSW Revenue Growth, EPS Growth & YoY Performance
NAMSW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.0M | -$39.5M | $-0.34 |
| Q3 2025 | $348.0K | -$16.6M | $-0.18 |
| Q2 2025 | $2.3M | -$17.4M | $-0.15 |
| Q1 2025 | $1.4M | -$39.5M | $-0.34 |
| Q3 2024 | $2.9M | -$16.6M | $-0.18 |
| Q2 2024 | $1.7M | -$38.3M | $-0.41 |
| Q1 2024 | $1.4M | -$42.0M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NewAmsterdam Pharma Co N.V. Dividends, Buybacks & Capital Allocation
NAMSW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NewAmsterdam Pharma Co N.V. (CIK: 0001936258)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NAMSW
What is the AI rating for NAMSW?
NewAmsterdam Pharma Co N.V. (NAMSW) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NAMSW's key strengths?
Claude: Strong cash position of $490M provides 3-4 year runway even at current burn rate. Minimal debt exposure with 0.00x debt-to-equity ratio and $85.9M total liabilities. ChatGPT: Robust cash balance and liquidity (7.9x current ratio). Debt-free capital structure with low liabilities.
What are the risks of investing in NAMSW?
Claude: Revenue collapse of 50.6% YoY to $22.5M indicates severe product, market, or competitive challenges. Operating loss of $225.7M on minimal revenue demonstrates fundamental business model breakdown. ChatGPT: Persistent large operating losses and deeply negative margins. Revenue contraction and low quality/visibility of revenue streams.
What is NAMSW's revenue and growth?
NewAmsterdam Pharma Co N.V. reported revenue of $22.5M.
Does NAMSW pay dividends?
NewAmsterdam Pharma Co N.V. does not currently pay dividends.
Where can I find NAMSW SEC filings?
Official SEC filings for NewAmsterdam Pharma Co N.V. (CIK: 0001936258) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NAMSW's EPS?
NewAmsterdam Pharma Co N.V. has a diluted EPS of $-1.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NAMSW's fundamental grade?
Based on our AI fundamental analysis in May 2026, NewAmsterdam Pharma Co N.V. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NAMSW stock overvalued or undervalued?
Valuation metrics for NAMSW: ROE of -29.8% (sector avg: 15%), net margin of -905.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NAMSW's AI grade for 2026?
Our dual AI analysis gives NewAmsterdam Pharma Co N.V. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NAMSW's free cash flow?
NewAmsterdam Pharma Co N.V.'s operating cash flow is $-147.8M, with capital expenditures of $246.0K. FCF margin is -657.8%.
How does NAMSW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -905.7% (avg: 12%), ROE -29.8% (avg: 15%), current ratio 7.88 (avg: 2).